Key facts
- It has raised $75.3M; the latest was Early Stage VC ($14.5M) in Mar 2026.
- Notable investors include 5Y Capital, Co-Win Ventures, Beijing Delian Yuntong Investment Management Company, New Alliance Capital, China InnoVision Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for iCAMUNO
- ·The full record, as it builds
Funding rounds
No funding rounds for iCAMUNO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iCAMUNO
Developer of a new generic off-the-shelf cell therapy drug intended to use somatic cell reprogramming technologies to benefit patients. The company provides medical research and experimental development by focusing on iPSC (Induced pluripotent stem cells), it applies iPSC, gene editing, stem cell differentiation, and other cutting-edge technologies to empower cells, it strives to innovate tumor immunology and regenerative medicine therapeutic solutions to provide patients with universal, effective and affordable cellular therapies, enabling cancer patients to get access to safe, fast, effective and affordable cell therapy solutions.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Employees
- 80
- Website
- icamunobio.com/
- Ownership
- Privately Held (backing)
iCAMUNO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iCAMUNO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iCAMUNO in its N-PORT filings yet. We sweep new filings monthly.